The short version of Reverse-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
This would explain the increase in lean body mass. GH has also been used experimentally to treat multiple sclerosis, to enhance weight loss in obesity, as well as in fibromyalgia, heart failure, Crohn's disease and ulcerative colitis, and burns. GH has also been used experimentally in patients with short bowel syndrome to lessen the requirement for intravenous total parenteral nutrition. In 1990, the US Congress passed an omnibus crime bill, the Crime Control Act of 1990, that amended the Federal Food, Drug, and Cosmetic Act, that classified anabolic steroids as controlled substances and added a new section that stated that a person who "knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services" has committed a felony. In 2019, the TRIIM trial paper showed that recombinant human growth hormone restores thymus function, improving the immune system and risk indices for many age‐related diseases. Despite off-label prescriptions being a normal and legal occurrence in medicine, in 2015 the Drug Enforcement Administration of the US Department of Justice published a position considering off-label prescriptions of HGH to be illegal, and to be a key path for illicit distribution of HGH.
Environmental consequences resulting from spraying have been criticized as detrimental to some of the world's most fragile ecosystems; the same spraying practices are further credited with causing health problems in local populations. A report by the RAND Corporation, examining the Colombian experience for insights applicable to the Mexican drug war, noted that "Plan Colombia has been widely hailed as a success, and some analysts believe that, by 2010, Colombian security forces had finally gained the upper hand once and for all." The report cited dramatic reductions in kidnappings and terrorist acts, and the recapture of territory, attributed to "a reinforced military and reinvigorated police force." It also found that, as of 2010, "Colombia is still a major source country for illicit narcotics. Moreover, the state continues to share sovereignty with a range of violent nonstate actors, including rebel groups and rightwing paramilitaries allied with drug traffickers and wealthy landowners." The Washington Office on Latin America concluded in 2010 that both Plan Colombia and the Colombian government's security strategy "came at a high cost in lives and resources, only did part of the job, are yielding diminishing returns and have left important institutions weaker."
== External links == Atrial+Natriuretic+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human NPPA genome location and NPPA gene details page in the UCSC Genome Browser. Overview of all the structural information available in the PDB for UniProt: P01160 (Natriuretic peptides A) at the PDBe-KB.
Research has focused on changing the mixture of keratins produced in the skin. There are 54 known keratin genes—of which 28 belong to the type I intermediate filament genes and 26 to type II—which work as heterodimers. Many of these genes share substantial structural and functional similarity, but they are specialized to cell type and/or conditions under which they are normally produced. If the balance of production could be shifted away from the mutated, dysfunctional keratin gene toward an intact keratin gene, symptoms could be reduced. For example, sulforaphane, a compound found in broccoli sprouts and few other vegetables, was found to reduce blistering in a mouse model to the point where affected pups could not be identified visually, when injected into pregnant mice (5 μmol/day = 0.9 mg) and applied topically to newborns (1 μmol/day = 0.2 mg in jojoba oil). As of 2008, clinical research at the University of Minnesota has explored allogeneic bone marrow transplantation for RD and junctional EB, treating a two-year-old child who is one of two brothers with EB. A second transplant has also been performed on the child's older brother. A Missouri boy has also successfully undergone the transplant, as well as a 5 year old boy from Alabama. So far there have been 12 successful transplants. Another transplant is scheduled for a California baby. A clinical trial is planned for 30 subjects. However, the immune suppression that bone marrow transplantation requires causes a risk of serious infections with large scale blisters and skin erosion.
== Early life and research == Hafezi was born in Remscheid, Germany in 1967, but he moved to Fribourg in Switzerland in 1981. He studied medicine in Fribourg and Bern, obtaining his Doctorate of Medicine at the Inselspital Bern under Prof. Dr. med Peter Weidmann, before going on in 1993, to undertake a two-year postgraduate course in Experimental Medicine and Biology at the University of Zürich. Hafezi spent three additional years at the University Hospital of Zurich, where he worked in the Laboratory for Retinal Cell Biology, which was part of the Department of Ophthalmology. Whilst studying in the Zürich laboratory, Hafezi identified the first known gene, c-Fos, that the absence of which could completely suppress light-induced apoptotic retinal degeneration. The group's findings were featured on the cover of the April 1997 edition of Nature Medicine. Hafezi then focused on a number of areas of cellular and retinal degeneration, in particular, light-induced photoreceptor death in the absence of p53 and JunD/AP-1, work that was published in IOVS and Cell Death & Differentiation, respectively. c-Fos and Fra1 are both components of the transcription factor AP-1, and in the year 2000, Hafezi and his colleagues presented work that showed that, in genetically engineered mice that express Fra1 where c-Fos is usually expressed, Fra1 can function in lieu of c-Fos to promote light-induced retinal photoreceptor death – work that was published in Genes & Development.
Sources: en.wikipedia.org
Natural Selection 2 is the sequel to Natural Selection. Natural Selection 2 started development using the Source Engine, but their development blog later announced [1] Archived 2011-07-20 at the Wayback Machine that Unknown Worlds had moved to the Spark engine, an engine they created themselves. Natural Selection 2 has the same basic gameplay as Natural Selection, but with new weapons and abilities. It was released commercially on Steam. According to an interview with the game director, Charlie Cleveland (Flayra), the sequel continues where the original left off and features environments that are dark and denser. Several gameplay modes once available only as community-developed mods (such as Marines vs. Marines) became officially supported. In addition, a major new feature of Natural Selection 2 is dynamic infestation [2] Archived 2006-12-23 at the Wayback Machine, released in December 2006. The proposed feature would dynamically generate bacterial infestation based on what areas of the map the alien team controlled. The alpha testing of Natural Selection 2 began on 26 July 2010. The game was released on October 30, 2012.
=== Pharmacodynamics === The measurement of plasma uric acid was used to evaluate the effectiveness of rasburicase in clinical studies. Following administration of either 0.15 or 0.20 mg/kg rasburicase daily for up to 5 days, plasma uric acid levels decreased within 4 hours and were maintained below 7.5 mg/dL in 98% of adult and 90% of pediatric patients for at least 7 days. There was no evidence of a dose response effect on uric acid control for doses between 0.15 and 0.20 mg/kg rasburicase.
Following this failure, a larger-scale version of the State Wula Agency was attempted in 1938 with the creation of the state-owned Xikang Animal Transport Company. This too had dismal results, as according to Liu (writing in a 1940 article), animals died en masse because Han colonists did not know how to take care of them and Kham herders had no incentive to do so. Once again, corruption was an issue, and the company was dissolved within a year after spending over 100,000 yuan. Despite this level of spending, it also suffered from a lack of veterinary medicine. A major debate over the wula system began after the collapse of both initiatives. One faction, led by Ren Zhuo, continued to call for abolishing the system to make way for state enterprise, Liu Wenhui, however, argued that the system would have to be kept and regulated due to the prior failures, and because it was the only major means of transportation in Kham. Another faction including Jiang Junzhang and the Frontier Administration Planning Commission argued for giving indigenous herders and other local voices more ownership and roles in company activities. There was a major ethnic dimension within this debate, because the anti-wula faction targeted the Kham herdsmen for their "obstinate" behavior and their control over the transport system.
=== Sponsor === The cost of a study depends on many factors, especially the number of sites conducting the study, the number of patients involved, and whether the study treatment is already approved for medical use. The expenses incurred by a pharmaceutical company in administering a phase III or IV clinical trial may include, among others:
This causes a slow accumulation of mutations and results in the development of cancers. An example of such a hereditary cancer syndrome is xeroderma pigmentosum, which causes the development of skin cancers in response to even minimal exposure to ultraviolet light.
Sources: en.wikipedia.org
The following year he was elected to membership at the Institute of Medicine. In 1987, he became Professor Emeritus of Medicine at Harvard Medical School. One year later he was the first Paul Klemperer Award recipient at the New York Academy of Medicine. In 1995, Gross won the Lifetime Achievement Award of The Wound Healing Society.
=== EDTA-dependent agglutination === In some individuals, clinically insignificant antibodies may cause in vitro agglutination of platelets. As a result of platelet clumping, platelet counts reported by automated counters may be much lower than the actual count in the blood because these devices cannot differentiate platelet clumps from individual cells. Pseudothrombocytopenia has been reported in association with the use of EDTA as an anticoagulant, with platelet cold agglutinins, and with multiple myeloma. Other risk factors associated with pseudothrombocytopenia are autoimmune diseases, infections, pregnancy and the treatment with some medications such as low-molecular-weight heparin, valproic acid, insulin, antibiotics and chemotherapy medications like sunitinib. The prevalence of pseudothrombocytopenia in K2-EDTA reported in different studies ranges from 0.03 to 0.27 percent in outpatients, which accounts for 15 to 30 percent of all cases of isolated thrombocytopenia. Tests can mistake small clumps of platelets for leukocytes, thus showing a pseudoleukocytosis in blood counts.
Hell Heaven pilots a lobster/fiddler crab–themed Kaijuki called Devil Capture (デビルキャプチャー, Debiru Kyapuchā) in an attempt to kidnap Princess Erika and distract the Dekarangers, but is deleted by Deka Blue while Devil Capture is destroyed by the Pat Striker in its Driving Sword formation. Hell Heaven is voiced by Keikō Sakai (酒井 敬幸, Sakai Keikō). Rikomoian Kevakia (リコモ星人ケバキーア, Rikomo Seijin Kebakīa): A digitally-based chameleon-themed being from Planet Rikomo who is capable of traveling through the internet and emerging from computers, but is powerless outside of one. He uses Hell Heaven to distract the Dekarangers while he kidnaps Princess Erika and ransoms her for her family's Wellness Stone. His physical body is deleted by Deka Red and Blue, but he successfully transfers his data into his personal Kaijuki, Devil Capture 2 (デビルキャプチャー2, Debiru Kyapuchā Tsū), and becomes its AI. Nevertheless, he is destroyed by Dekaranger Robo. Kevakia is voiced by Kōji Tobe (戸部 公爾, Tobe Kōji). Anrian Beildon (アンリ星人ベイルドン, Anri Seijin Beirudon): A rhinoceros-themed criminal from Planet Anri who possesses an armored body and is charged with mass-murder on five planets. While working for the scientist Mano Mark, Beildon turns humans into gasoline for a share of his employer's profits and commits bank robberies to help Mark fund his work until the latter is deleted by the Dekarangers via the D-Bazooka. Beildon is voiced by Kenta Miyake (三宅 健太, Miyake Kenta).
=== Misinformation === TikTok has banned Holocaust denial, but other conspiracy theories have become popular on the platform, such as Pizzagate and QAnon (two conspiracy theories popular among the US alt-right) whose hashtags reached almost 80 million views and 50 million views respectively by June 2020. The platform has also been used to spread misinformation about the COVID-19 pandemic, such as clips from Plandemic. TikTok removed some of these videos and has generally added links to accurate COVID-19 information on videos with tags related to the pandemic. In January 2020, left-leaning media watchdog Media Matters for America said that TikTok hosted misinformation related to the COVID-19 pandemic despite a recent policy against misinformation. In April 2020, the government of India asked TikTok to remove users posting misinformation related to the COVID-19 pandemic. There were also multiple conspiracy theories that the government is involved with the spread of the pandemic. It reported that in the second half of 2020, over 340,000 videos in the US about election misinformation and 50,000 videos of COVID-19 misinformation were removed. To combat misinformation in the 2022 midterm election in the US, TikTok announced a midterms Elections Center available in-app to users in 40 different languages. TikTok partnered with the National Association of Secretaries of State to give accurate local information to users.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.